Cancer Research Center of Lyon (CRCL) - INSERM U1052, Lyon, France; IIT Centre for Life Nanoscience (CLNS), Rome, Italy; Dept of Internal Medicine (DMISM), Sapienza University, Rome, Italy.
Inserm, UMR-1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue Contre le Cancer, Institut Universitaire d'Hematologie, Paris, France; Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche Santé, Médecine, Biologie Humaine, Bobigny, France; Université Paris Diderot, Paris, France.
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021.
Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through direct and indirect mechanisms. HBV DNA integration into the host genome occurs at early steps of clonal tumor expansion and induces both genomic instability and direct insertional mutagenesis of diverse cancer-related genes. Prolonged expression of the viral regulatory protein HBx and/or altered versions of the preS/S envelope proteins dysregulates cell transcription and proliferation control and sensitizes liver cells to carcinogenic factors. Accumulation of preS1 large envelope proteins and/or preS2/S mutant proteins activates the unfold proteins response, that can contribute to hepatocyte transformation. Epigenetic changes targeting the expression of tumor suppressor genes occur early in the development of HCC. A major role is played by the HBV protein, HBx, which is recruited on cellular chromatin and modulates chromatin dynamics at specific gene loci. Compared with tumors associated with other risk factors, HBV-related tumors have a higher rate of chromosomal alterations, p53 inactivation by mutations and overexpression of fetal liver/hepatic progenitor cells genes. The WNT/β-catenin pathway is also often activated but HBV-related tumors display a low rate of activating β-catenin mutations. HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.
乙型肝炎病毒 (HBV) 通过直接和间接机制促进肝细胞癌 (HCC) 的发展。HBV DNA 整合到宿主基因组发生在克隆肿瘤扩张的早期步骤,并诱导基因组不稳定性和多种癌症相关基因的直接插入突变。病毒调节蛋白 HBx 的长期表达和/或前 S/S 包膜蛋白的改变版本失调细胞转录和增殖控制,并使肝细胞对致癌因素敏感。前 S1 大包膜蛋白和/或前 S2/S 突变蛋白的积累激活未折叠蛋白反应,这可能有助于肝细胞转化。针对肿瘤抑制基因表达的表观遗传变化在 HCC 的早期发展中发生。HBV 蛋白 HBx 起着主要作用,它被募集到细胞染色质上,并调节特定基因座的染色质动力学。与与其他危险因素相关的肿瘤相比,HBV 相关的肿瘤具有更高的染色体改变率、突变导致的 p53 失活和胎儿肝脏/肝祖细胞基因的过表达。WNT/β-catenin 途径也经常被激活,但 HBV 相关的肿瘤显示出较低的激活 β-catenin 突变率。HBV 相关的 HCC 可能发生在非肝硬化的肝脏上,这进一步支持了 HBV 通过触发共同和病因特异性致癌途径以及刺激宿主免疫反应和驱动肝脏慢性坏死性炎症,在肝脏转化中发挥直接作用的观点。